Merck Stock News

Pharmaceutical company Merck (MRK) will acquire cancer drugmaker Harpoon Therapeutics (HARP) in a deal valued at $680 million. The closing of the acquisition is currently pending, awaiting approval fr

Merck (MRK) begins global pivotal studies on bomedemstat, nemtabrutinib, MK-2870 and MK-5684.

Merck stock is shrugging off seven months of underperformance, shooting more than 7% higher in the first week of 2024.

J&J, Merck and Boston Scientific kicked off the year's biggest medical conference with a trio of takeovers. AMAM stock and HARP stock soared.

Merck is a pharmaceutical giant whose medications and vaccines play key roles in the fight against viruses, cancer, and cardiovascular diseases. On October 26, 2023, Merck published results for the 3r

Merck has struck a deal to buy clinical-stage immunotherapy company Harpoon Therapeutics for about $680 million.

Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio with immunotherapies.

Merck & Co Inc (NYSE:MRK) is close to acquiring Harpoon Therapeutics Inc, a cancer drug developer, for about $700 million to bolster its oncology portfolio. The proposed deal, which could value Harpo

Merck MRK, +0.18% is in talks to buy cancer drugmaker Harpoon Therapeutics HARP, -1.49% for about $700 million, or $23 per share, Bloomberg News reported, citing people familiar with the matter. Merck

Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday, citing people familiar with the matter.

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi

The Health Care Select Sector SPDR Fund NYSEARCA: XLV, which has both growth and defensive characteristics, was the leader in the first week of the year. Top sector performers included Moderna Inc. NA

'Mad Money' host Jim Cramer talks stocks he is watching as the Magnificent 7 struggles in the new year.

Merck & Co's Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.

In the latest trading session, Merck (MRK) closed at $114.77, marking a +1.35% move from the previous day.